<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078465</url>
  </required_header>
  <id_info>
    <org_study_id>NFH20170307</org_study_id>
    <nct_id>NCT03078465</nct_id>
  </id_info>
  <brief_title>Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI</brief_title>
  <acronym>PL-PLATELET</acronym>
  <official_title>Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of Ticagrelor versus Clopidogrel for the reduction of
      adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel
      after successful implantation of coronary drug-eluting stents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, single-blind, investigator-initiated study with a
      parallel design. Patients with coronary artery disease undergoing percutaneous coronary
      intervention and presenting high platelet reactivity on clopidogrel as assessed with the
      PL-11 analyzer (platelet maximum aggregation ratio [MAR%] ≥ 55 %) at 2 hours post-clopidogrel
      300mg LD (Day 0), will be randomized after informed consent, in a 1:1 ratio to the following
      treatment groups:

      Group Α: Ticagrelor 180 mg immediate loading (on Day 0) followed by 180mg/day starting from
      Day 1 until Day 365 (12 months after randomization).

      Group Β: Clopidogrel 150mg per day, starting from Day 1 until Day 365 (12 months after
      randomization).

      Platelet reactivity assessment will be performed before randomization (Day 0), and 3-day
      after randomization (Day 3). Documentation of major adverse cardiac and cerebrovascular
      events (death, myocardial infarction, stent thrombosis, stroke, revascularization procedure
      with PCI or CABG) and serious adverse events (bleeding, other adverse events) will be
      performed until 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-Month Freedom From MACE</measure>
    <time_frame>12 months</time_frame>
    <description>Major adverse cardiovascular and cerebrovascular events consist of all-cause death, target vessel myocardial infarction, stroke, stent thrombosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>12-Month Freedom From Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Month Freedom From Cardiac death</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Month Freedom From MI</measure>
    <time_frame>12 months</time_frame>
    <description>Myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Month Freedom From TLR</measure>
    <time_frame>12 months</time_frame>
    <description>Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Month Freedom From TVR</measure>
    <time_frame>12 months</time_frame>
    <description>Target vessel revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Month Freedom From Stent Thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Stent thrombus was classified as definite, probable, or possible, according to the definitions provided by the Academic Research Consortium (ARC).Regarding timing, ST was defined as early (&lt;30 days), late (30 days to 1 year), or too late (&gt;1 year).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Month Freedom From Stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Stroke</description>
  </secondary_outcome>
  <other_outcome>
    <measure>12-Month Freedom From BARC type 2 or above bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>BARC (Bleeding Academic Research Consortium) type 2 or above bleeding event following the first dose of study medication</description>
  </other_outcome>
  <other_outcome>
    <measure>12-Month Freedom From Major or minor bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Major or minor bleeding defined by TIMI (thrombolysis in myocardial infarction) bleeding criteria</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1050</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of ticagrelor 180mg/day for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of clopidogrel 150 mg/day for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Daily administration of ticagrelor 180mg for 12 months</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>BRILINTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Daily administration of clopidogrel 150mg for 12 months</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix, Talcom</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who agreed to the experimental plan which was permitted by IRB;

          -  Patients planned to take dual antiplatelet therapy for 12 months.

        Exclusion Criteria:

          -  Severe hepatic dysfunction defined as serum transaminase &gt; 3 times normal limit;

          -  Renal dysfunction defined as eGFR &lt; 30ml/min/1.73m^2;

          -  Co-morbidity with an estimated life expectancy of &lt; 50 % at 12 months;

          -  Scheduled surgery in the next 12 months, which resulted protocol changes;

          -  Known allergy against study drug or device;

          -  Use of glycoprotein IIb/IIIa inhibitor during the perioperative period;

          -  Anticoagulation treatment including warfarin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shao-Liang Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shao-Liang Shao, MD</last_name>
    <phone>+86-25-52208351</phone>
    <email>chmengx@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Kan, MPH</last_name>
    <phone>+86-25-52271398</phone>
    <email>kanjingok@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoliang Chen, MD</last_name>
      <phone>+86 13605157029</phone>
      <email>chmengx@126.com</email>
    </contact>
    <investigator>
      <last_name>Shaoliang Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junjie Zhang, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang JJ, Gao XF, Ge Z, Tian NL, Liu ZZ, Lin S, Ye F, Chen SL. High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention. BMC Cardiovasc Disord. 2016 Nov 29;16(1):240.</citation>
    <PMID>27894260</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Shaoliang Chen</investigator_full_name>
    <investigator_title>Vice President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

